Change in the organizational structure of the GIF

The draft regulation provides for a change in the organizational structure of the General Pharmaceutical Inspectorate by dividing it into an inspection part and a part for carrying out supervisory tasks other than inspections. Currently, inspections are carried out by manufacturing inspectors, who are located in the Department of Manufacturing Inspection of the Main Pharmaceutical Inspectorate, and wholesale inspectors, who are located in the Department of Supervision of the Main Pharmaceutical Inspectorate. In order to manage the inspection system more efficiently, it is envisaged that all inspectors will be located in one department - the Inspection Department of the Main Pharmaceutical Inspectorate. In addition, tasks not directly related to the performance of inspections will be transferred from the Inspection Department for Manufacturing to a new department - the Department of Pharmaceutical Supervision.

The above changes will improve the efficiency of the Main Pharmaceutical Inspectorate's operations, as each department will perform activities of one type. For example, supervision of the quality of medicinal products, which is not directly related to conducting inspections, will be placed in the Department of Pharmaceutical Supervision.

The draft regulation also provides for the Chief Pharmaceutical Inspector to be able to appoint support teams, if necessary. Until now, the regulation did not provide for this possibility. The Chief Pharmaceutical Inspector will be able to appoint opinion bodies to consult external experts on matters related to the office's activities.

Source: RCL